Medication Quick Facts
📋Overview
Rystiggo (rozanolixizumab-noli) is a neonatal Fc receptor (FcRn) blocker. This medication works by binding to the FcRn, which prevents the recycling of immunoglobulin G (IgG) antibodies back into the bloodstream.
By lowering the concentration of these antibodies, the drug helps manage the underlying biological process where the immune system attacks the body's own tissues. This reduction in antibody levels is intended to address symptoms like muscle weakness and fatigue.
🛡️ Educational information only
This content is provided for general health education and awareness and is based on publicly available medical information. It is not intended to replace professional medical advice, diagnosis, or treatment, and should not be used to make healthcare decisions. Always seek the guidance of a qualified healthcare professional regarding any medical condition, medication, supplement, or procedure.
Found an Error?
Help us keep this information accurate. If you notice any incorrect details, please submit a correction request.
